Dosing problems of gentamicin in critically ill patients

Area of Science:

• Pharmacology
• Critical Care Medicine
• Infectious Diseases

Background:

• Gram-negative sepsis is a life-threatening condition requiring effective antibiotic therapy.
• Gentamicin is an aminoglycoside antibiotic commonly used for Gram-negative infections.
• Optimizing gentamicin dosing is crucial to balance efficacy and minimize toxicity.

Purpose of the Study:

• To evaluate the efficacy and safety of different gentamicin sulphate dosing frequencies (8-hour vs. 12-hour) in critically ill patients with Gram-negative sepsis.
• To assess the pharmacokinetic variability of gentamicin in this patient population.
• To investigate the incidence of gentamicin-induced nephrotoxicity.

Main Methods:

• Twenty critically ill patients with Gram-negative sepsis received daily gentamicin sulphate via intravenous short infusion.
• Patients were randomized to either an 8-hour or 12-hour dosing frequency regimen.
• Plasma gentamicin levels, renal function markers (serum creatinine), and urine parameters were monitored throughout treatment.

Main Results:

• Significant inter- and intra-patient variability in plasma gentamicin concentrations was observed.
• Nephrotoxicity occurred in only one patient despite daily gentamicin administration.
• No significant difference in favorable treatment response was noted between the 8-hour and 12-hour dosing groups.

Conclusions:

• Gentamicin dosing frequency may not significantly impact treatment outcomes in Gram-negative sepsis.
• High peak gentamicin concentrations achieved with short infusions may be effective against Gram-negative bacteria.
• Further research is warranted to understand gentamicin pharmacokinetics and optimize dosing strategies in critically ill patients.